I’m surprised this story isn’t getting a bit more play, i.e. the move by Blue Cross Blue Shield of Massachusetts to stop covering popular weight-loss drugs for non-diabetics, as the Globe reports. … BCBS says it’s responding to widespread complaints from employers about the high cost of GLP-1 meds like Ozempic and WeGovy. But I think it’s safe to say Blue Cross’s recent $400 million operating loss also had something to do with the decision. The Globe piece makes clear other insurers and providers are struggling under the financial weight of GLP-1 meds (pun not intended — originally).